Neil Woodford’s High Income Fund Farewell: Wm. Morrison Supermarkets plc, Rentokil Initial plc And Sanofi SA

Woodford’s mega-million moves on Wm. Morrison Supermarkets plc (LON:MRW), Rentokil Initial plc (LON:RTO) and Sanofi SA (NYSE:SNY).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford announced last October that he was calling time on his quarter-century career with asset management group Invesco Perpetual. Britain’s most celebrated money manager handed over control of his Invesco funds last month, and will shortly launch his own equity income vehicle from his new Woodford Investment Management business.

Invesco has just published the final annual report under Woodford’s tenure of the £13.5bn flagship High Income fund. The report reveals some of the City wizard’s last mega-million moves for the fund, including big trades in Wm. Morrison Supermarkets (LSE: MRW), Rentokil Initial (LSE: RTO) and Sanofi (NYSE: SNY.US).

Woodford’s share buys and sells during the first half of the year were balanced. However, the second half of the year saw net sales of around £1bn, as Woodford paid out to investors who pulled out of the fund after the announcement of his departure.

We saw a trimming of many holdings to raise the £1bn, but there were also some large positions that Woodford exited completely.

Wm. Morrison Supermarkets

Woodford disposed of the High Income fund’s 68.4 million shares in Morrisons, raising a whopping £187m. The numbers give a sale price of about 273p a share. Whether Woodford had become disillusioned with his former supermarket favourite, or was getting shot of a company his successor wasn’t keen on, is a moot point.

Either way, it was a timely sale, as the shares are currently trading at not much more than 200p — representing 14 times forecast earnings with a potential income of 6.5%.

It will be interesting to see whether Woodford buys back into Morrisons for his new fund. I see the supermarket as being in a similar position to AstraZeneca a couple of years ago, when the contrarian Woodford was piling into the then-unloved pharmaceuticals firm.

Rentokil Initial

Rentokil, which has a wider range of hygiene businesses than the soubriquet ‘royal rat catcher’ suggests, is another holding Woodford has binned. The sale of the High Income fund’s substantial stake in the mid-cap firm raised £117m. My sums say Woodford sold at about 105p a share, compared with 116p today.

Like Morrisons, Rentokil trades on a forward P/E of 14, but the prospective dividend yield is much lower at 2.2%. Woodford originally bought into Rentokil as “a significant restructuring opportunity”. The bulk of the restructuring has been done, and it remains to be seen whether Woodford thinks the story has further to run and buys back into Rentokil for his new fund.

Sanofi

Given the outflow of money from the High Income fund, and the net £1bn of share sales to cover the redemptions, I was surprised to find Woodford actually increasing the fund’s stake in some companies.

Woodford added modestly to a few of his Footsie favourites, including Imperial Tobacco, GlaxoSmithKline and Centrica, but substantially upped the fund’s stake in French drugs giant Sanofi. He increased the holding by almost 50% during the course of the year, spending in the region of £100m.

The Paris-listed company, which can also be traded on the New York stock exchange, is on a forward P/E of 14 — the same as FTSE counterpart GlaxoSmithKline. Analysts have Sanofi delivering faster earnings growth over the next couple of years, but GlaxoSmithKline offering a higher dividend.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester does not own any shares mentioned in this article. The Motley Fool has recommended shares in Morrisons and GlaxoSmithKline.

More on Investing Articles

A pastel colored growing graph with rising rocket.
Investing Articles

Is this FTSE 100 passive income superstar also its best bargain right now?

This FTSE 100 gem still looks to me like one of the best bargains in the index. It appears very…

Read more »

Investing Articles

If I’d put £10,000 into Meta stock at the start of 2024, here’s what I’d have now

Our writer looks at the year-to-date performance of Meta stock and considers whether he'd consider buying this magnificent tech share.

Read more »

Hand arranging wood block stacking as step stair on paper pink background
Investing Articles

Investing £5 a day in this dividend giant can make me a £14,067 annual second income!

This FTSE 100 high-yield star can make me a major second income, supported by a strong business outlook and an…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Taylor Wimpey shares yield a fabulous 6.41%, but is the dividend safe?

Harvey Jones has enjoyed plenty of growth and income after buying Taylor Wimpey shares last year. But is today's high…

Read more »

Yellow number one sitting on blue background
Investing Articles

1 FTSE lithium stock I think could be ready to rocket

Jon Smith explains why the lithium price could be due a rally, and why shares of one related FTSE stock…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
US Stock

This growth stock that Warren Buffett owns just hit 52-week lows. Should I buy?

Jon Smith flags up a high-profile US stock that the great Warren Buffett bought back in 2020 but which has…

Read more »

White female supervisor working at an oil rig
Investing Articles

Could the UK general election be bad news for this FTSE 250 energy producer?

The country is due to vote in the general election on 4 July. Our writer looks at the possible implications…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Should we buy cheap FTSE 100 shares now, before it’s too late?

The FTSE 100 is up 5% so far in 2024 and hit an all-time high in May. That means the…

Read more »